Ladybon tablets 2.5mg, No. 28

treatment of symptoms of estrogen deficiency in postmenopausal women;

prevention of osteoporosis in postmenopausal women with a high risk of fractures and with intolerance to other groups of drugs used to prevent osteoporosis.

Inside. The tablets must be swallowed with water, preferably at the same time of day.

LadyboneЃ should be taken 12 months after the last natural menstrual period. If you start taking LadyibonЃ earlier than the specified period, then the likelihood of irregular bleeding / bleeding from the vagina increases. Before starting to take LadyibonЃ, malignant neoplasms of the reproductive system should be excluded, regardless of whether the woman is taking another hormone replacement therapy (HRT) drug or not, especially in case of bleeding from the genital tract.

The dose of the drug is 1 table / day.

No dose adjustment for age is required.

Blisters with LadyboneЃ are marked with the days of the week. You should start taking the drug with the tablet marked for the current day. For example, if the day of admission coincides with Monday, then it is necessary to take the pill marked Monday from the top row of the blister. Then take the tablets according to the days of the week. From the next blister, tablets are taken without gaps and breaks. Avoid skipping the medication when changing the blister or packaging.

When treating with LedibonЃ, there is no need to add gestagen-containing drugs.

If the next pill is missed, further tactics depend on the time of delay of the planned intake. If less than 12 hours have passed since the pill was missed, you must take the missed pill as soon as possible. If the delay in taking the pills is more than 12 hours, you should skip the appointment and take the next pill at the usual time.

It is not recommended to take 2 tablets. at the same time to replenish the missed dose.

Switching from a cyclic or continuous regimen of taking the drug for HRT to tibolone

When switching from a cyclic regimen of taking the drug for HRT, treatment with LadyboneЃ should be started the next day after the completion of the previous treatment regimen. In the case of a transition from a continuous regimen of taking the combined HRT drug, treatment can be started at any time.

established hypersensitivity to the active substance or any excipient of the drug;

a period less than a year after the last menstruation;

diagnosed (including in history) breast cancer or suspicion of it;

diagnosed (including in history) malignant estrogen-dependent tumors (for example, endometrial cancer) or suspicion of them;

vaginal bleeding of unknown etiology;

untreated endometrial hyperplasia;

thrombosis (venous or arterial) and thromboembolism currently or in history (including deep vein thrombosis and thrombophlebitis, pulmonary embolism, myocardial infarction, ischemic or hemorrhagic cerebrovascular disorders);

diagnosed thrombophilic conditions (for example, a deficiency of protein C, protein S or antithrombin III) (see 'Special instructions');

conditions preceding thrombosis (including transient ischemic attacks, angina pectoris), currently or in history;

severe or multiple risk factors for the development of venous or arterial thrombosis (including atrial fibrillation, complicated lesions of the heart valve apparatus and subacute bacterial endocarditis; uncontrolled arterial hypertension; extended surgery, accompanied by prolonged immobilization; extensive trauma; obesity (body mass index> 30 kg / m2), smoking over the age of 35);

cardiovascular failure in the stage of decompensation;

a history of acute liver disease or liver disease after which liver function tests have not returned to normal;

liver failure;

malignant or benign liver tumors (including liver adenoma), currently or in history;

porphyria;

otosclerosis that occurred during a previous pregnancy or with the use of hormonal contraceptive drugs in history;

rare hereditary diseases: galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption;

pregnancy;

period of breastfeeding.

Carefully

If any of the following conditions / diseases are present, have been observed previously and / or have worsened during pregnancy or previous hormone therapy, the patient should be under close medical supervision. Such conditions / diseases include:

leiomyoma (uterine fibroma) and / or endometriosis;

cardiovascular failure without signs of decompensation;

the presence of risk factors for estrogen-dependent tumors (for example, the presence of breast cancer in the next of kin (mother, sisters);

controlled arterial hypertension;

increased concentration of cholesterol in the blood;

disorders of carbohydrate metabolism, diabetes mellitus, both in the presence and in the absence of complications;

cholelithiasis;

migraine or severe headache;

systemic lupus erythematosus;

a history of endometrial hyperplasia;

epilepsy;

bronchial asthma;

renal failure;

otosclerosis not associated with pregnancy or previous use of hormonal contraceptive drugs.

It should be borne in mind that these conditions / diseases may recur or worsen during treatment with tibolone.